MENARINI FRANCE

What MENARINI FRANCE does

MENARINI FRANCE S.A. (legal name: Laboratoires MENARINI France S.A.) is the French operating subsidiary of the Menarini Group, an Italian pharmaceutical group founded in 1886 and headquartered in Florence since 1915. The French entity is structured as a Société Anonyme, employs approximately 159 staff, and is based in Rungis, Île-de-France. It operates exclusively within France, distributing prescription pharmaceuticals, consumer healthcare products, diagnostics, and aesthetic medicine brands through wholly-owned operating arms including A.Menarini Diagnostic and Relife France.

The company's commercial portfolio spans nine prescription therapeutic areas — pneumology, allergology, diabetology, cardiology, metabolic, neurology, traumatology, sexology, and antibiotics — alongside consumer healthcare brands such as Novalac (infant nutrition), PROSTAMOL (urinary wellbeing), MILDAC (depression support), and BIOCIDAN (ophthalmology eye drops). In September 2023 the firm received European Commission approval for ORSERDU® (elacestrant) in ER+/HER2- metastatic breast cancer with ESR1 mutations, marking its entry into oncology commercialization in France. Underlying technology assets center on a pharmacovigilance safety database, GDPR-compliant personal data infrastructure (Article 9.2.(i)), and HCP reference data sourced from IQVIA's OneKey directory; no AI/ML capabilities are disclosed.

MENARINI FRANCE monetises primarily through one-time product sales of regulated pharmaceuticals and consumer health SKUs, with pricing controlled by French health authorities rather than market negotiation. Its go-to-market combines a field sales force of medical representatives (délégués médicaux) promoting prescription brands to physicians and pharmacists, hospital and clinical supply channels, and pharmacy distribution for OTC products. Commercial activity is governed by an AFNOR-certified quality framework aligned with the French pharmaceutical promotion charter, and the firm operates within the Menarini Group's 140-country global footprint under family ownership.

Name

MENARINI FRANCE

Legal name

Laboratoires MENARINI France S.A.

Website

https://menarini.fr

Company type

Private

Operating status

Operating

Headcount range

101–250 employees

Short description

MENARINI FRANCE S.A. is the French subsidiary of Italy's Menarini Group, distributing prescription pharmaceuticals across nine therapeutic areas, consumer healthcare products, diagnostics, and aesthetic medicine brands to healthcare professionals and patients across France.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Male Reproductive & Sexual Medicine (Andrology) (HLAKAOAD), Men’s Health (OTC Urologic & Sexual Health) (HLAIADAK), Hand Hygiene & Skin Antisepsis (Soaps, Sanitizers, Surgical Scrubs, CHG Prep) (HLAHANAE)

Keywords

• Prescription pharmaceuticals
• Consumer healthcare products
• Medical diagnostics systems
• Aesthetic medicine products
• Infant nutrition supplements

Headquarters

HQ city

Rungis

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D

Revenue model

1. Pharmaceutical Products: Development, production and marketing of prescription medications across multiple therapeutic areas including pneumology, allergology, diabetology, cardiology, metabolic, neurology, traumatology, sexology, and antibiotics.
2. Consumer Healthcare: Over-the-counter health products including cosmeceuticals, infant nutrition (Novalac), vitamins, urinary wellbeing supplements, depression support, ophthalmology, antiseptics, and halitosis treatments.
3. Diagnostic Products: A.Menarini Diagnostic division provides diagnostic solutions and products.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

MENARINI FRANCE is the French subsidiary of the Menarini Group, operating as a pharmaceutical company that develops, registers, and distributes prescription medications across multiple therapeutic areas (pneumology, allergology, diabetology, cardiology, oncology, gynecology, urology, gastroenterology, ophthalmology). It also markets consumer healthcare products (infant nutrition brand Novalac, dietary supplements PROSTAMOL and MILDAC, ophthalmology drops BIOCIDAN), in-vitro diagnostic solutions under A.Menarini Diagnostic, and aesthetic medicine products through the Relife brand.

Product overview

MENARINI FRANCE is a pharmaceutical company offering prescription medications across multiple therapeutic areas (pneumology, allergology, diabetology, cardiology, metabolic, neurology, traumatology, sexology, antibiotics) and consumer healthcare products including infant nutrition (Novalac), cosmecuticals, vitamins, and dietary supplements. The portfolio includes specialized products like ORSERDU® for breast cancer treatment, A.Menarini Diagnostic for diagnostics, Relife Company for aesthetic medicine, and branded products like PROSTAMOL for urinary health and MILDAC for depression. The company operates under the global Menarini Group founded in Italy in 1886 and present in 140 countries.

Differentiator

Problem solved

Functional benefit

Brands

• NHS: Aesthetic medicine division operating under Menarini France
• A.Menarini Diagnostic

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Four partnerships are on record, tiered core and supporting.

• A. Menarini DiagnosticcoreOthersDiagnostic division of the Menarini Group providing in vitro diagnostic products. The division operates its own website (menarinidiagnostics.fr) and offers diagnostic solutions for healthcare professionals.
• Relife CompanycoreOthersAesthetic medicine and dermatology subsidiary of the Menarini Group, focused on skincare and aesthetic products. Operates independently at relifecompany.fr with heritage focus on innovation in dermatology.
• Istituto per il Credito Sportivo e CulturalesupportingStrategic or Co-development PartnerInstitutional partner supporting the Fair Play Menarini International Award program, contributing to the organization's social responsibility and sportsmanship initiatives.
• Sky (Sky Italia)supportingGTM or Marketing PartnerBroadcasting partner for the Fair Play Menarini International Award ceremony, airing the annual event on Sky channels 501 and 257 to reach sports audiences across Italy.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Bayer France: French subsidiary of Bayer AG operating both pharmaceutical (cardiology, women's health, oncology) and consumer health (OTC, diagnostics) businesses through a field sales force. Same multi-channel Rx+OTC GTM structure as Menarini France.
• Servier: French privately-held mid-cap pharmaceutical group operating across multiple therapeutic areas (cardiology, oncology, diabetes, neurology) with a consumer-healthcare arm. Highly comparable to Menarini France in size, therapeutic breadth, private ownership model, and French/European commercial footprint.
• Pierre Fabre: French pharmaceutical and dermo-cosmetic company with a portfolio spanning prescription drugs, OTC consumer healthcare (incl. infant nutrition, dermatology), and a dedicated Relife-style aesthetic/dermatology division. Closely mirrors Menarini France's Rx + consumer health + aesthetic medicine mix.
• Ipsen: French specialty pharmaceutical company headquartered near Paris, focused on oncology, neurology, and consumer healthcare. Similar therapeutic-area spread, French base, and private/public crossover profile.
• Stada: German-headquartered European pharma company combining generics, branded specialty pharma (incl. urology, cardiology), and a sizable consumer healthcare portfolio. Comparable consumer-healthcare + specialty-pharma dual model.
• Recordati: Italian family-controlled mid-cap pharmaceutical company with a rare-disease specialty franchise plus a broader primary-care and consumer-health book. Similar Italian-heritage multi-therapeutic structure and family-ownership governance to Menarini Group.
• Boehringer Ingelheim France: French subsidiary of the German family-owned Boehringer Ingelheim group covering respiratory, cardiometabolic, and specialty therapeutics. Comparable as another family-owned mid-cap European pharma operating through a French national sales organization.

Broad incumbents

• Novartis France: Major Swiss pharmaceutical company with a substantial French subsidiary covering cardiovascular, oncology, ophthalmology, and immunology. Operates the same field-sales + hospital-channel GTM in France, with overlapping therapeutic categories.
• Sanofi France: France's largest pharmaceutical company with a deep French primary-care, specialty, vaccine, and consumer-healthcare portfolio. Significantly larger than Menarini France, but operates in exactly the same therapeutic/consumer-health segments and competes for the same HCP detailing time.
• Roche France: Global pharmaceutical and diagnostics leader with a French subsidiary pairing oncology and specialty pharmaceuticals with an in-vitro diagnostics division (cobas). Direct parallel to Menarini France's combined pharmaceuticals + A.Menarini Diagnostics structure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/menarini-france

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MENARINI FRANCE